Microsatellite unstable gastrointestinal neuroendocrine carcinomas: A new clinicopathologic entity

Endocrine-Related Cancer

Volumn 22, Issue 1, 2015, Pages 35-45

  Sahnane, Nora ^a   Furlan, Daniela ^a   Monti, Matilde ^a   Romualdi, Chiara ^b   Vanoli, Alessandro ^c   Vicari, Emanuela ^a   Solcia, Enrico ^c   Capella, Carlo ^a   Sessa, Fausto ^a   La Rosa, Stefano ^d  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Gene methylation; MANEC; Microsatellite instability; Mismatch repair; NEC; Neuroendocrine carcinomas

Indexed keywords

B RAF KINASE; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; FEMALE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL CARCINOMA; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METHYLATION; MICROSATELLITE INSTABILITY; NEUROENDOCRINE CARCINOMA; NEUROENDOCRINE TUMOR; ONCOGENE K RAS; PYROSEQUENCING; CARCINOMA; COHORT ANALYSIS; DNA METHYLATION; GASTROINTESTINAL TUMOR; GENETICS; MIDDLE AGED; MISMATCH REPAIR; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NEUROENDOCRINE; COHORT STUDIES; DNA METHYLATION; DNA MISMATCH REPAIR; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED;

EID: 84923618154     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0410     Document Type: Article

References (46)

1. Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB et al. 2009 Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. Journal of Clinical Oncology 27 1814-1821. (doi:10.1200/JCO.2008.18.2071)
2. Bevilacqua RA & Simpson AJ 2000 Methylation of the hMLH1 promoter but no hMLH1 mutations in sporadic gastric carcinomas with high-level microsatellite instability. International Journal of Cancer 87 200-203. (doi:10.1002/1097-0215(20000715)87:2<200::AID-IJC7>3.0.CO;2-I)
3. Boland CR, Shin SK & Goel A 2009 Promoter methylation in the genesis of gastrointestinal cancer. Yonsei Medical Journal 50 309-321. (doi:10.3349/ymj.2009.50.3.309)
4. Bras-Goncalves RA, Rosty C, Laurent-Puig P, Soulie P, Dutrillaux B & Poupon MF 2000 Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. British Journal of Cancer 82 913-923. (doi:10.1054/bjoc.1999.1019)
5. Dacic S, Finkelstein SD, Baksh FK, Swalsky PA, Barnes LE & Yousem SA 2002 Small-cell neuroendocrine carcinoma displays unique profiles of tumor-suppressor gene loss in relationship to the primary site of formation. Human Pathology 33 927-932. (doi:10.1053/hupa.2002.126875)
6. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, Garcia-Sanz R et al. 2003 Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17 2257-2317. (doi:10.1038/sj.leu.2403202)
7. Duval A, Rolland S, Compoint A, Tubacher E, Iacopetta B, Thomas G & Hamelin R 2001 Evolution of instability at coding and non-coding repeat sequences in human MSI-H colorectal cancers. Human Molecular Genetics 10 513-518. (doi:10.1093/hmg/10.5.513)
8. Fraley F & Raftery AE 2002 Model-based clustering, discriminant analysis, and density estimation. Journal of the American Statistical Association 97 611-631. (doi:10.1198/016214502760047131)
9. Furlan D, Casati B, Cerutti R, Facco C, Terracciano L, Capella C & Chiaravalli AM 2002 Genetic progression in sporadic endometrial and gastrointestinal cancers with high microsatellite instability. Journal of Pathology 197 603-609. (doi:10.1002/path.1162)
10. Furlan D, Bernasconi B, Uccella S, Cerutti R, Carnevali I & Capella C 2005 Allelotypes and fluorescence in situ hybridization profiles of poorly differentiated endocrine carcinomas of different sites. Clinical Cancer Research 11 1765-1775. (doi:10.1158/1078-0432.CCR-04-1732)
11. Furlan D, Sahnane N, Mazzoni M, Pastorino R, Carnevali I, Stefanoli M, Ferretti A, Chiaravalli AM, La Rosa S & Capella C 2013 Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum. Virchows Archiv 462 47-56. (doi:10.1007/s00428-012-1348-2)
12. Gausachs M, Mur P, Corral J, Pineda M, Gonzalez S, Benito L, Menendez M, Espinas JA, Brunet J, Iniesta MD et al. 2012 MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. European Journal of Human Genetics 20 762-768. (doi:10.1038/ejhg.2011.277)
13. Ghimenti C, Lonobile A, Campani D, Bevilacqua G & Caligo MA 1999 Microsatellite instability and allelic losses in neuroendocrine tumors of the gastro-entero-pancreatic system. International Journal of Oncology 15 361-366. (doi:10.3892/ijo.15.2.361)
14. Gologan A & Sepulveda AR 2005 Microsatellite instability and DNA mismatch repair deficiency testing in hereditary and sporadic gastrointestinal cancers. Clinics in Laboratory Medicine 25 179-196. (doi:10.1016/j.cll.2004.12.001)
15. Guidoboni M, Gafa R, Viel A, Doglioni C, Russo A, Santini A, Del Tin L, Macri E, Lanza G, Boiocchi M et al. 2001 Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. American Journal of Pathology 159 297-304. (doi:10.1016/S0002-9440(10)61695-1)
16. Hijioka S, Hosoda W, Mizuno N, Hara K, Imaoka H, Bhatia V, Mekky MA, Tajika M, Tanaka T, Ishihara M et al. 2014 Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas? Journal of Gastroenterology [in press]. (doi:10.1007/s00535-014-0987-2)
17. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk CM et al. 2012 Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Research 22 271-282. (doi:10.1101/gr.117523.110)
18. Ionov Y, Peinado MA, Malkhosyan S, Shibata D & Perucho M 1993 Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363 558-561. (doi:10.1038/363558a0)
19. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM & Kolodner R 1997 Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Research 57 808-811.
20. Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N & Allegra CJ 2007 Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. Journal of Clinical Oncology 25 767-772. (doi:10.1200/JCO.2006.05.8172)
21. La Rosa S & Sessa F 2014 High-grade poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: from morphology to proliferation and back. Endocrine Pathology 25 193-198. (doi:10.1007/s12022-014-9316-9)
22. La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A, Doglioni C, Capella C & Solcia E 2009 Improved histologic and clinico-pathologic criteria for prognostic evaluation ofpancreatic endocrine tumors. Human Pathology 40 30-40. (doi:10.1016/j.humpath.2008.06.005)
23. La Rosa S, Inzani F, Vanoli A, Klersy C, Dainese L, Rindi G, Capella C, Bordi C & Solcia E 2011 Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Human Pathology 42 1373-1384. (doi:10.1016/j.humpath.2011.01.018)
24. La Rosa S, Marando A, Furlan D, Sahnane N & Capella C 2012a Colorectal poorly differentiated neuroendocrine carcinomas and mixed adeno-neuroendocrine carcinomas: insights into the diagnostic immuno-phenotype, assessment of methylation profile, and search for prognostic markers. American Journal of Surgical Pathology 36 601-611. (doi:10.1097/PAS.0b013e318242e21c)
25. La Rosa S, Marando A, Sessa F & Capella C 2012b Mixed adenoneuro-endocrine carcinomas (MANECs) of the gastrointestinal tract: an update. Cancers 4 11-30. (doi:10.3390/cancers4010011)
26. Lubensky IA & Zhuang Z 2007 Molecular genetic events in gastrointestinal and pancreatic neuroendocrine tumors. Endocrine Pathology 18 156-162. (doi:10.1007/s12022-007-9007-x)
27. Naert K & Dupre MP 2012 Large cell neuroendocrine carcinoma arising in a sessile serrated adenoma: a novel observation. Human Pathology 43 757-760. (doi:10.1016/j.humpath.2011.07.022)
28. Nassar H, Albores-Saavedra J & Klimstra DS 2005 High-grade neuroendocrine carcinoma of the ampulla of vater: a clinicopathologic and immunohistochemical analysis of 14 cases. American Journal of Surgical Pathology 29 588-594. (doi:10.1097/01.pas.0000157974.05397.4f)
29. Park JH, Park J, Choi JK, Lyu J, Bae MG, Lee YG, Bae JB, Park DY, Yang HK, Kim TY et al. 2011 Identification of DNA methylation changes associated with human gastric cancer. BMC Medical Genomics 4 82. (doi:10.1186/1755-8794-4-82)
30. Parwani AV, Geradts J, Caspers E, Offerhaus GJ, Yeo CJ, Cameron JL, Klimstra DS, Maitra A, Hruban RH & Argani P 2003 Immunohisto-chemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions. Modern Pathology 16 299-308. (doi:10.1097/01.MP.0000062656.60581.AA)
31. Percesepe A, Pedroni M, Sala E, Menigatti M, Borghi F, Losi L, Viel A, Genuardi M, Benatti P, Roncucci L et al. 2000 Genomic instability and target gene mutations in colon cancers with different degrees of allelic shifts. Genes, Chromosomes & Cancer 27 424-429. (doi:10.1002/(SICI)1098-2264(200004)27:4<424::AID-GCC13>3.0.CO;2-M)
32. Power DG, Asmis TR, Tang LH, Brown K & Kemeny NE 2010 High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease. Medical Oncology 28 (Suppl 1) S169-S174. (doi:10.1007/s12032-010-9674-1)
33. Rindi G, Arnold R & Bosman FT 2010 Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In WHO Classification of Tumours of the Digestive System, Ed F Bosman. Lyon: IARC Press.
34. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK & Slattery ML 2005 Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129 837-845. (doi:10.1053/j.gastro.2005.06.020)
35. Schwarz G 1978 Estimating the dimension of a model. Annals of Statistics 6 461-464. (doi:10.1214/aos/1176344136)
36. Shia J, Tang LH, Weiser MR, Brenner B, Adsay NV, Stelow EB, Saltz LB, Qin J, Landmann R, Leonard GD et al. 2008 Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? American Journal of Surgical Pathology 32 719-731. (doi:10.1097/PAS.0b013e318159371c)
37. Smith J & Reidy-Lagunes D 2013 The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas. Seminars in Oncology 40 100-108. (doi:10.1053/j.seminoncol.2012.11.011)
38. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K et al. 2013 Predictive and prognosticfactors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Annals of Oncology 24 152-160. (doi:10.1093/annonc/mds276)
39. Stelow EB, Moskaluk CA & Mills SE 2006 The mismatch repair protein status of colorectal small cell neuroendocrine carcinomas. American Journal of Surgical Pathology 30 1401-1404. (doi:10.1097/01.PAS.0000213272.15221.38)
40. Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B & Hamelin R 2002 Evaluation of tumor microsatellite instability usingfive quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123 1804-1811. (doi:10.1053/gast.2002.37070)
41. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB & Issa JP 1999 Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Research 59 5438-5442.
42. Vélayoudom-Céphise FL, Duvillard P, Foucan L, Hadoux J, Chougnet CN, Leboulleux S, Malka D, Guigay J, Goere D, Debaere T et al. 2013 Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocrine-Related Cancer 20 649-657. (doi:10.1530/ERC-13-0027)
43. Walsh MD, Clendenning M, Williamson E, Pearson SA, Walters RJ, Nagler B, Packenas D, Win AK, Hopper JL, Jenkins MA et al. 2013 Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Modern Pathology 26 1642-1656. (doi:10.1038/modpathol.2013.101)
44. Xu Y, Hu B, Choi AJ, Gopalan B, Lee BH, Kalady MF, Church JM & Ting AH 2012 Unique DNA methylome profiles in CpG island methylator phenotype colon cancers. Genome Research 22 283-291. (doi:10.1101/gr.122788.111)
45. Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, de Wilde RF, Maitra A, Hicks J, Demarzo AM et al. 2012 Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. American Journal of Surgical Pathology 36 173-184. (doi:10.1097/PAS.0b013e3182417d36)
46. Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A, Tiret E, Dumont S, Gayet B, Validire P et al. 2010 Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Annals of Oncology 21 772-780. (doi:10.1093/annonc/mdp383)